Meridian Bioscience Preliminary FY2017 Revenues Beat Estimates

Oct 19, 2017

NEW YORK (GenomeWeb) – Meridian Bioscience issued preliminary fiscal year 2017 earnings before the opening of the market today, reporting a 2 percent year-over-year increase in revenues.

Meridian expects revenues of $200.5 million for its fiscal year ending Sept. 30, 2017, including fourth quarter revenues of $49.5 million. Non-GAAP earnings per share should be in the $.66 to $.67 range for the year, according to the firm.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu